secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303251
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences & GSK collaborate on oligonucleotide drugs; $170M upfront, up to $3.3B milestones
--------------------------------------------------------------------------------

- Upfront payment: $170M ($120M cash + $50M equity investment at $4.68/share, a 15% premium to 30-day VWAP).
- Total eligible milestones up to $3.3B: WVE-006 ($225M dev/launch + $300M commercial); 8 GSK programs (up to $1.2B + $1.6B).
- GSK gets exclusive global license to WVE-006, a preclinical RNA editing candidate for alpha-1 antitrypsin deficiency.
- Wave leads preclinical research for all programs; GSK takes over at IND-enabling for its programs. Wave leads first-in-patient for WVE-006.
- Cash runway extended into 2025; deal expected to close in Q1 2023 pending HSR antitrust clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/0001193125-22-303251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/d432281d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer